Butyrophilin subfamily 2 member A1 (BTN2A1)

BTN2A1 (Butyrophilin subfamily 2 member A1) is a widely expressed, variably glycosylated type I transmembrane glycoprotein of the butyrophilin family in the Ig-superfamily[1][3][7]. Its extracellular domain contains two Ig-like domains (IgV and IgC), and its cytoplasmic region holds a B30.2 domain[1][6]. BTN2A1 operates as an immune checkpoint receptor, playing a critical role in activating Vγ9Vδ2 T cells by directly binding their TCR and forming complexes with BTN3A1, enabling the recognition of self- and microbe-derived phosphoantigens[2][4][6][8][10]. BTN2A1 impacts antigen presentation, immune surveillance, and is linked to susceptibility for metabolic disorders and cancer. Mutations and polymorphisms in BTN2A1 are associated with conditions like diabetes and hypertension[1]. It is under active investigation as a target for cancer immunotherapy, especially strategies harnessing γδ T cell responses[2][4][8][10]. BTN2A1 is not currently the direct target of any approved therapeutic drugs, but its central role in immune checkpoint regulation and γδ T cell activation makes it a promising candidate for future immunomodulatory therapies[5][8][10].

Other names

Butyrophilin subfamily 2 member A1BTF1BT2.1Butyrophilin 2A1

Drugs or molecules targeting BTN2A1 would act as immune modulators—by enhancing or blocking its interaction with T cell receptors (TCRs), especially the Vγ9Vδ2 TCR[2][4][6][8][10]. Synergizes with BTN3A1 to facilitate phosphoantigen sensing and activate T cells[4][6][8].